Traders should monitor upcoming clinical trial milestones and data readouts, as success could validate IDE849's potential and lead to future partnerships or accelerated development. However, no immediate revenue or financial impact is expected.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 9 $31.00entry
- T+1 · 7mo ago −1.61%α −1.55% · $30.50
- T+5 · 7mo ago +4.87%α +1.69% · $32.51
- T+20 · 6mo ago −7.29%α −14.86% · $28.74
- T+60 · 4mo ago +27.00%α +16.22% · $39.37
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
IDEAYA Biosciences announced a clinical collaboration with AstraZeneca to evaluate its investigational drug IDE849 in combination with AstraZeneca's Imfinzi for treating extensive-stage small cell lung cancer. The study will be globally sponsored by IDEAYA, with AstraZeneca supplying the drug.
Key Facts
- IDEAYA Biosciences entered into a clinical collaboration agreement with AstraZeneca on April 8, 2026.
- The collaboration will evaluate IDE849 (a DLL3 TOP1 antibody-drug conjugate) in combination with Imfinzi (durvalumab) in extensive-stage small cell lung cancer (SCLC).
- IDEAYA will sponsor the global Phase 1 clinical trial, while AstraZeneca will supply Imfinzi.
- The trial is part of a broader multi-site global Phase 1 study in DLL3 upregulated solid tumors, including SCLC, neuroendocrine carcinomas, neuroendocrine tumors, and melanoma.
Financial Impact
Undisclosed financial terms; IDEAYA will sponsor the study, and AstraZeneca will supply Imfinzi.
Risk Factors
- Clinical trial may not meet efficacy or safety endpoints.
- Regulatory delays or trial enrollment challenges could slow development.
- Dependence on third-party collaborator (AstraZeneca) for supply and trial success.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-148777 |
| Document: 0001193125-26-148777-index-headers.html | 0001193125-26-148777 |
| Document: 0001193125-26-148777-index.html | 0001193125-26-148777 |
| Document: 0001193125-26-148777.txt | 0001193125-26-148777 |
Track record
13 reports on IDYA
2 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +15.66% at T+60 after the Apr 13, 2026 report. 3 of 5 went positive at some point.
Filters
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $31.33 to $31.75 Now $30.36 −3.10% ▲ +1.34% +1.93% vs SPY
- Nov 3, 202613d ago 8-K Neutral 5/10 Entry $31.33 to $31.75 Now $30.36 −3.10% ▲ +1.34% +1.93% vs SPY
- Oct 6, 20265w ago 144 Bearish 6/10 Entry $36.26 to $33.86 Now $30.36 +16.27% ▲ +6.62% +5.64% vs SPY
- Aug 4, 202614w ago 8-K Neutral 4/10 Entry $36.11 to $36.84 Now $30.36 −15.92% ▲ +2.02% +2.12% vs SPY
- Jun 23, 202620w ago 8-K Neutral 2/10 Entry $36.28 to $36.17 Now $30.36 −16.32% ▼ −0.30% −2.01% vs SPY
- Jun 10, 202622w ago 8-K Bearish 6/10 Entry $28.84 to $31.26 Now $30.36 −5.27% ▼ −8.39% −7.96% vs SPY
- Jun 9, 202622w ago 424B5 Bearish 6/10 Entry $27.60 to $30.57 Now $30.36 −10.00% ▼ −10.76% −7.33% vs SPY
- Jun 8, 202623w ago 424B5 Bearish 6/10 Entry $28.07 to $30.23 Now $30.36 −8.16% ▼ −7.70% −5.28% vs SPY
- Jun 3, 202623w ago 8-K Neutral 4/10 Entry $28.40 to $27.60 Now $30.36 +6.90% ▼ −2.82% +1.00% vs SPY
- May 5, 202627w ago 8-K Neutral 2/10 Entry $28.74 to $28.12 Now $30.36 +5.64% ▼ −2.16% −3.29% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers